Aurinia Pharmaceuticals (AUPH) Stock Price, Quote, News & History | Benzinga

Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, News & History

AUPHNASDAQ

Trade with Public

Trade with Public

$16.65

-0.62-3.59%

At close: Aug 21, 5:00 PM EST

$16.65

N/A

After Hours: 4:46 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$17.20

Close

$16.65

Volume / Avg.

1.25M / 1.48M

Day Range

$16.63 - $17.32

52 Wk Range

10.34 - 19.25

Market Cap

$2.22B

P/E Ratio

7.57

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

7.9%

Days to Cover

9.44

Recent Aurinia Pharmaceuticals Inc. News

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.

Vandana Singh

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.

Henry Khederian

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Aurinia Pharmaceuticals shares are trading lower Thursday afternoon after the lupus-focused drugmaker posts a blowout fourth quarter and raises expectations for continued growth in 2026.

Henry Khederian

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse

FDA drug center head George Tidmarsh resigned after accusations of misusing power to harm a former business associate. He denies wrongdoing.

Vandana Singh

US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.

Rishabh Mishra

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

175.24M

Investing Cash Flow (TTM)

12.84M

Financing Cash Flow (TTM)

-61.25M

Free Cash Flow (TTM)

175.07M

Capital Expenditure (TTM)

-176.00K

Net Change in Cash (TTM)

126.83M

Analyst Trends and Forecast

0

0

0

0

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.8

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.84B

PE Ratio (TTM)

7.57

PE Ratio (FWD)

17.67

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.56

PB Ratio (TTM)

3.74

Earnings Yield % (TTM)

13.20%

Earnings Yield % (FWD)

5.66%

EV / EBITDA (TTM)

10.44

Price / EBITDA (TTM)

12.81

Price / Free Cash Flow (TTM)

13.45

Book Value / Share

$4.62

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$13.99M

Total Cash

$179.83M

Debt to Equity

0.10

Issuance of Debt (TTM)

-$13.99M

Repayment of Debt (TTM)

-$13.99M

Key Statistics

Open

$17.20

Close

$16.65

Volume / Avg.

1.25M / 1.48M

Day Range

$16.63 - $17.32

52 Wk Range

10.34 - 19.25

Market Cap

$2.22B

P/E Ratio

7.57

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

7.9%

Days to Cover

9.44

About

Sector

Health Care

Industry

Biotechnology

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Aurinia Pharmaceuticals (AUPH) stock?

A

You can purchase shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Aurinia Pharmaceuticals (AUPH) competitors?

A

Other companies in Aurinia Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Aurinia Pharmaceuticals (AUPH) stock?

A

Aurinia Pharmaceuticals has a consensus price target of $15.50.

Q

What is the current price for Aurinia Pharmaceuticals (AUPH)?

A

The stock price for Aurinia Pharmaceuticals (NASDAQ: AUPH) is $16.65 last updated August 21, 2026 at 4:46 PM EDT.

Q

Does Aurinia Pharmaceuticals (AUPH) pay a dividend?

A

There are no upcoming dividends for Aurinia Pharmaceuticals.

Q

When is Aurinia Pharmaceuticals (NASDAQ:AUPH) reporting earnings?

A

Aurinia Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Aurinia Pharmaceuticals (AUPH) going to split?

A

There is no upcoming split for Aurinia Pharmaceuticals.

Q

What sector and industry does Aurinia Pharmaceuticals (AUPH) operate in?

A

Aurinia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.